Search results for " Capa"

showing 10 items of 1248 documents

Aerobic performance capacity in athletes

1978

Maximal oxygen uptake (max\(\dot V\)O2) in leg and arm work, succinate dehydrogenase activity (SDH) and percentage of slow twitch fibers (%ST fibers) in M. vastus lateralis (VL), M. gastrocnemius c.l. (GL) and M. deltoideus (D) were studied in 89 athletes practising 11 different sport events. It was found that maximal oxygen uptake correlated positively with %ST fibers and SDH activity in M. VL. The SDH activity and %ST fibers in M. VL correlated also with one another. The results suggest that oxidative capacity of the muscles is not the limiting factor for maximal oxygen uptake. The role of the oxidative capacity of the muscles might be important during submaximal work of long duration and…

Malemedicine.medical_specialtyPhysiologySports MedicineMuscle massOxygen ConsumptionPhysiology (medical)Internal medicinemedicineHumansOrthopedics and Sports MedicineShort durationbiologyChemistryAthletesMusclesSuccinate dehydrogenasePublic Health Environmental and Occupational HealthVO2 maxGeneral MedicineHuman physiologybiology.organism_classificationElectrophysiologySuccinate DehydrogenaseEndocrinologybiology.proteinOxidative capacityFemaleEuropean Journal of Applied Physiology and Occupational Physiology
researchProduct

Home-based inspiratory muscle training for management of older patients with heart failure with preserved ejection fraction: does baseline inspirator…

2019

Background:Heart failure with preserved ejection fraction is a clinical syndrome characterised by reduced exercise capacity. Some evidence has shown that a simple and home-based programme of inspiratory muscle training offers promising results in terms of aerobic capacity improvement in patients with heart failure with preserved ejection fraction. This study aimed to investigate whether the baseline inspiratory muscle function predicts the changes in aerobic capacity (measured as peak oxygen uptake; peak VO2) after a 12-week home-based programme of inspiratory muscle training in patients with heart failure with preserved ejection fraction.Methods:A total of 45 stable symptomatic patients wi…

Malemedicine.medical_specialtyRehabilitation Nursing030204 cardiovascular system & hematologyBreathing Exercises03 medical and health sciences0302 clinical medicineOlder patientsInternal medicinemedicineHumans030212 general & internal medicineClinical syndromeAerobic capacityAgedHeart FailureAdvanced and Specialized NursingExercise Tolerancebusiness.industryInspiratory muscle trainingStroke VolumeInspiratory muscleExercise capacityHome basedinspiratory muscle functionaerobic capacityMedical–Surgical NursingHeart failure with preserved ejection fractionCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessMuscle ContractionEuropean Journal of Cardiovascular Nursing
researchProduct

Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in pati…

2010

Background: Epidemiologic studies indicate that elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients (pts) with chronic heart failure (CHF). Clinical trials with b-blockers suggest that HR reduction is an important mechanism of their benefit in pts with stable CHF. Pharmacologic inhibition of the If current now provides the opportunity of pure HR reduction. The purpose of this study was to evaluate the impact of ‘‘Off-Label’’ use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in pts with ischemic CHF. Methods: Between January 2008 and June 2008, a graded maximal exercise test with re…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaAdrenergic beta-AntagonistsOff-label uselaw.inventionOxygen ConsumptionQuality of lifeRandomized controlled triallawHeart RateInternal medicinemedicineHumansPharmacology (medical)IvabradineExercise physiologyRisk factorExercisePharmacologyHeart Failureivabradine heart failure exercise capacityNeurotransmitter AgentsExercise Tolerancebusiness.industryOff-Label UseBenzazepinesmedicine.diseaseClinical trialHeart failureChronic DiseaseCardiologyExercise TestQuality of LifeFemaleCardiology and Cardiovascular MedicinebusinessIvabradinemedicine.drugJournal of cardiovascular pharmacology and therapeutics
researchProduct

Cardiorespiratory fitness measured with cardiopulmonary exercise testing and mortality in patients with cardiovascular disease: A systematic review a…

2021

Highlights • High cardiorespiratory fitness (CRF) in patients with cardiovascular disease (CVD) is associated with 58% lower all-cause mortality risk and 73% lower cardiovascular mortality risk compared to unfit counterparts. • Each 1 metabolic equivalent (1-MET) increase in CRF is associated with a 19% lower CVD mortality risk among patients with CVD. • Coronary artery disease patients with high CRF have a 68% lower all-cause mortality risk than their unfit counterparts. • Each 1-MET increase in CRF is associated with a 17% lower all-cause mortality risk among patients with coronary artery disease. • No significant associations were found between increments of 1-MET and lower mortality ris…

Malemedicine.medical_specialtySurvivalPopulationPhysical Therapy Sports Therapy and RehabilitationHeart failureReviewLower riskCoronary artery diseaseMetabolic equivalentCoronary artery disease03 medical and health sciencesCardiopulmonary fitness0302 clinical medicineInternal medicineExercise capacityMedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineProspective StudiesProspective cohort studyeducationeducation.field_of_studybusiness.industryHazard ratioCardiorespiratory fitness030229 sport sciencesmedicine.diseaseConfidence intervalCardiorespiratory FitnessCardiovascular DiseasesGV557-1198.995Sports medicineExercise TestFemalebusinessRC1200-1245SportsJournal of Sport and Health Science
researchProduct

Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

2018

BackgroundSodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HypothesisWe postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. MethodsNineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30days after initiation of empagliflozin therapy. A mixe…

Malemedicine.medical_specialtyTime FactorsClinical InvestigationsEmpagliflozinRenal functionPilot ProjectsWalk Test030204 cardiovascular system & hematology03 medical and health sciencesExercise Capacity0302 clinical medicineOxygen ConsumptionQuality of lifeGlucosidesInterquartile rangeInternal medicineEmpagliflozinmedicineHumansHypoglycemic Agents030212 general & internal medicineProspective StudiesBenzhydryl CompoundsProspective cohort studyAgedHeart FailureExercise Tolerancebusiness.industryRepeated measures designType 2 Diabetes MellitusGeneral MedicineRecovery of FunctionMiddle AgedEmpagliflozin Exercise Capacity Heart Failuremedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2Heart failureCardiologyQuality of LifeFemaleCardiology and Cardiovascular MedicinebusinessPulmonary Ventilation
researchProduct

Mean velocity of the pulmonary artery estimated by cardiac magnetic resonance as an early prognostic predictor in heart failure.

2018

Background and objective: To identify early, non-invasive prognostic indicators in heart failure (HF), with and without associated pulmonary hypertension, by means of cardiac magnetic resonance, and oxidative stress and anti-inflammatory biomarkers such as Trolox (TM) (antioxidant status) and IL-10 (anti-inflammatory cytokine). Patients and methods: We prospectively included 70 patients admitted for new-onset HF. During index admission, mean velocity of the pulmonary artery (mvPA) was measured, and blood Trolox (TM) and IL-10 determined. The study sample was divided in two groups according to the optimal cut-off value for event prediction calculated by the ROC curve (mvPA = 8 cm/s), conside…

Malemedicine.medical_specialtyTime FactorsHypertension PulmonaryPopulationPulmonary Artery03 medical and health sciences0302 clinical medicinePredictive Value of Testsmedicine.arteryInternal medicinemedicineHumans030212 general & internal medicineProspective StudieseducationSurvival analysisAgedHeart Failureeducation.field_of_studyOxygen Radical Absorbance Capacitybusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseasePrognosisPulmonary hypertensionMagnetic Resonance ImagingInterleukin-10Log-rank testCardiac Imaging TechniquesHeart failurePulmonary arteryCardiologyFemaleCardiac magnetic resonancebusinessBlood Flow VelocityMedicina clinica
researchProduct

Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study

2018

Background: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubilril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. Methods and results: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30 days after initiation of sacubitril/valsartan therapy. A mixed-effects model …

Malemedicine.medical_specialtyTime FactorsTetrazolesPilot ProjectsWalk Test030204 cardiovascular system & hematologySacubitrilCohort Studies03 medical and health sciencesAngiotensin Receptor AntagonistsElectrocardiography0302 clinical medicineInternal medicineExercise capacityMedicineHumans6-minute walk test030212 general & internal medicineEnalaprilProspective StudiesSacubitril/valsartanAgedAged 80 and overEjection fractionExercise Tolerancebusiness.industryAminobutyratesBiphenyl CompoundsExercise capacityMiddle Agedmedicine.diseaseHeart failure with reduced ejection fractionDrug CombinationsTreatment OutcomeValsartanHeart failureCardiologyValsartanFemaleCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

Does Transfer Capacitive Resistive Energy Has a Therapeutic Effect on Peyronie's Disease? Randomized, Single-Blind, Sham-Controlled Study on 96 Patie…

2017

<b><i>Background/Aims/Objectives:</i></b> We have investigated the clinical and physiological effects of Transfer Capacitive Resistive Energy (TCARE) therapy on men with Peyronie's disease (PD). <b><i>Methods:</i></b> Ninety-six men with PD have been randomized in a 2:1 ratio to receive 3 sessions of TCARE therapy or sham therapy. Pain, penile curvature and erectile function have been assessed before the first treatment and up to 9 months after the end of treatment, using the Visual Analogue Scale for the pain, a goniometer to measure the degree of curvature using at-home photography and an International Index of Erectile Function (IIEF-5) que…

Malemedicine.medical_specialtyTime FactorsVisual analogue scalePeyronie's diseaseUrologyPenile Induration030232 urology & nephrologyPain reliefPainElectric Stimulation TherapyElectric Capacitance03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesElectric ImpedanceMedicineHumansSingle-Blind MethodAdverse effectPenile painAgedPain MeasurementResistive touchscreenErectile failure; Induratio penis plastic; Penile pain; Penis plaque; Peyronie's disease; Transfer capacitive resistive energy; Urology030219 obstetrics & reproductive medicinebusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaPenile ErectionInduratio penis plasticTransfer capacitive resistive energyTherapeutic effectRecovery of FunctionMiddle Agedmedicine.diseaseTreatment OutcomeTolerabilityItalyPhysical therapyPenile painPeyronie's diseasebusinessErectile failurePenis plaquePenisUrologia internationalis
researchProduct

Effects of inspiratory muscle training in patients with heart failure with preserved ejection fraction

2013

Heart failure with preserved ejection fraction (HFpEF) is remarkably common in elderly people with highly prevalent comorbid conditions. Despite its increasing in prevalence, there is no evidence-based effective therapy for HFpEF. We sought to evaluate whether inspiratory muscle training (IMT) improves exercise capacity, as well as left ventricular diastolic function, biomarker profile and quality of life (QoL) in patients with advanced HFpEF and nonreduced maximal inspiratory pressure (MIP).A total of 26 patients with HFpEF (median (interquartile range) age, peak exercise oxygen uptake (peak VO2) and left ventricular ejection fraction of 73 years (66-76), 10 ml/min/kg (7.6-10.5) and 72% (6…

Malemedicine.medical_specialtyTime Factorsanimal structuresEpidemiologyDiastoleBreathing ExercisesVentricular Function LeftWalking distanceDiastoleInternal medicinemedicineHumansElderly peopleIn patientProspective StudiesAgedHeart FailureExercise ToleranceEjection fractionbusiness.industryInspiratory muscle trainingStroke VolumeRecovery of FunctionMiddle AgedExercise capacityRespiratory MusclesTreatment OutcomeSpainExercise TestQuality of LifeCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessBiomarkersEuropean Journal of Preventive Cardiology
researchProduct

Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study

2017

Malemedicine.medical_specialtyTreatment outcomeTetrazolesPilot Projects030204 cardiovascular system & hematology030226 pharmacology & pharmacyAngiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeprilysinAgedHeart FailureExercise ToleranceEjection fractionbusiness.industryAminobutyratesBiphenyl CompoundsStroke VolumeGeneral MedicineExercise capacitymedicine.diseaseDrug CombinationsTreatment OutcomeHeart failureCardiologyValsartanFemaleNeprilysinbusinessSacubitril ValsartanRevista Española de Cardiología (English Edition)
researchProduct